Endocyte, Inc.
(NASDAQ : ECYT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
ABBVAbbVie, Inc. -1.53%89.331.9%$1150.39m
JNJJohnson & Johnson -0.49%143.850.7%$1050.38m
BMYBristol-Myers Squibb Co. -0.49%60.031.0%$962.49m
MRKMerck & Co., Inc. -0.03%77.240.7%$834.15m
PFEPfizer Inc. -0.44%37.330.9%$827.89m
LLYEli Lilly & Co. -2.27%144.601.1%$414.21m
AZNAstraZeneca Plc -2.11%51.991.2%$248.80m
NVSNovartis AG -1.00%84.200.2%$155.21m
GSKGlaxoSmithKline Plc 0.10%40.790.2%$137.47m
NVONovo Nordisk A/S -1.45%62.480.1%$84.39m
SNYSanofi 0.06%47.300.2%$79.60m
RGENRepligen Corp. -5.41%126.147.1%$66.10m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -2.15%58.720.0%$44.79m
ARCTArcturus Therapeutics Holdings, Inc. -29.67%38.190.0%$38.70m
RETAReata Pharmaceuticals, Inc. -3.37%152.453.4%$36.51m

Company Profile

Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.